Published in J Pharm Pharmacol on May 01, 1967
Rapid detection of certain basic drugs in urine. Br Med J (1971) 0.75
N-Methyl-benzylamine, a metabolite of pargyline in man. Br J Clin Pharmacol (1979) 0.75
Inhibition of antipyrine metabolism by beta-adrenoceptor antagonists. Br J Clin Pharmacol (1981) 3.07
Oxidation phenotype--a major determinant of metoprolol metabolism and response. N Engl J Med (1982) 2.72
Determination of debrisoquine and its 4-hydroxy metabolite in biological fluids by gas chromatography with flame-ionization and nitrogen-selective detection. J Chromatogr (1977) 2.43
Amiodarone pharmacokinetics. Am Heart J (1983) 2.42
Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol (1981) 2.38
Buccal absorption of basic drugs and its application as an in vivo model of passive drug transfer through lipid membranes. J Pharm Pharmacol (1967) 2.32
Urinary excretion kinetics of amphetamine in man. J Pharm Pharmacol (1965) 2.11
Inhibition of oxidative drug metabolism by beta-adrenoceptor antagonists in related to their lipid solubility. Br J Clin Pharmacol (1981) 2.08
Binding of anilide-type local anesthetics in human plasma. I. Relationships between binding, physicochemical properties, and anesthetic activity. Anesthesiology (1970) 1.71
The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol (1992) 1.71
Polymorphic hydroxylation of debrisoquine. Lancet (1977) 1.69
Plasma concentrations of local anaesthetics after interscalene brachial plexus block. Br J Anaesth (1977) 1.66
Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies. Br J Clin Pharmacol (1985) 1.64
Lack of effect of atenolol on antipyrine clearance. Br J Clin Pharmacol (1982) 1.51
Determination of nicotine and its metabolite, cotinine, in urine by gas chromatography. Nature (1966) 1.48
Clinical pharmacokinetics of local anaesthetics. Clin Pharmacokinet (1979) 1.47
Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment. Pharmacogenetics (1996) 1.41
Gerontokinetics--a reappraisal. Br J Clin Pharmacol (1992) 1.41
Meperidine kinetics in man. Intravenous injection in surgical patients and volunteers. Clin Pharmacol Ther (1975) 1.39
Ketorolac trometamol for postoperative analgesia after orthopaedic surgery. Br J Anaesth (1992) 1.38
Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem Pharmacol (1997) 1.37
Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. J Pharmacol Exp Ther (1988) 1.37
Measurement of the renal clearance of drugs. Br J Clin Pharmacol (1981) 1.35
Metoprolol and debrisoquin metabolism in Nigerians: lack of evidence for polymorphic oxidation. Clin Pharmacol Ther (1986) 1.32
Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices. Br J Clin Pharmacol (1986) 1.29
Lignocaine and indocyanine green kinetics in patients following myocardial infarction. Br J Clin Pharmacol (1980) 1.28
Why hypertensive patients vary in their response to oral debrisoquine. Br Med J (1977) 1.25
Prediction of in vivo drug clearance from in vitro data. I: impact of inter-individual variability. Xenobiotica (2006) 1.24
Oxidation of methamphetamine and methylenedioxymethamphetamine by CYP2D6. Drug Metab Dispos (1997) 1.23
Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolizers. Clin Pharmacol Ther (1983) 1.22
Population pharmacokinetics of methadone in opiate users: characterization of time-dependent changes. Br J Clin Pharmacol (1999) 1.21
A collection of therapeutic, toxic and fatal blood drug concentrations in man. Hum Toxicol (1983) 1.17
The disposition of debrisoquine in hypertensive patients. Br J Clin Pharmacol (1978) 1.16
Enterocytic CYP3A4 in a paediatric population: developmental changes and the effect of coeliac disease and cystic fibrosis. Br J Clin Pharmacol (2001) 1.15
The mechanism of oxidation of amphetamine enantiomorphs by liver microsomal preparations from different species. J Pharm Pharmacol (1972) 1.11
The analysis of nicotine-1'-N-oxide in urine, in the presence of nicotine and cotinine, and its application to the study of in vivo nicotine metabolism in man. J Pharm Pharmacol (1971) 1.11
Inter-individual variability in levels of human microsomal protein and hepatocellularity per gram of liver. Br J Clin Pharmacol (2003) 1.11
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is N-demethylated by cytochromes P450 2D6, 1A2 and 3A4--implications for susceptibility to Parkinson's disease. J Pharmacol Exp Ther (1996) 1.11
Circulating levels of lignocaine after peri-oral injections. Br Dent J (1975) 1.11
Lactic acidosis during metformin treatment in an elderly diabetic patient with impaired renal function. Acta Med Scand (1981) 1.11
Circadian hydrocortisone infusions in patients with adrenal insufficiency and congenital adrenal hyperplasia. Clin Endocrinol (Oxf) (2006) 1.10
Pharmacokinetic aspects of intravenous regional anesthesia. Anesthesiology (1971) 1.10
A model for steroid transport across biological membranes. J Pharm Pharmacol (1975) 1.10
Metabolism of amphetamines. Identification of N-oxygenated products by gas chromatography and mass spectrometry. J Pharm Pharmacol (1973) 1.10
Mechanism-based inactivation of CYP2D6 by methylenedioxymethamphetamine. Drug Metab Dispos (2004) 1.10
Altered plasma drug binding in cancer: role of alpha 1-acid glycoprotein and albumin. Clin Pharmacol Ther (1982) 1.08
Meperidine and other basic drugs: general method for their determination in plasma. J Pharm Sci (1974) 1.08
Polymorphic metabolism of beta-adrenoceptor antagonists. Br J Clin Pharmacol (1984) 1.08
Timolol and atenolol: relationships between oxidation phenotype, pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol (1985) 1.07
Selective inhibition of alternative oxidative pathways of nicotine metabolism. Chem Biol Interact (1971) 1.07
Metabolic oxidation of aliphatic basic nitrogen atoms and their alpha-carbon atoms. Xenobiotica (1974) 1.07
Enzyme induction in man caused by smoking. Nature (1967) 1.06
Systemic absorption of mepivacaine in commonly used regional block procedures. Anesthesiology (1972) 1.06
Absorption metabolism and excretion of the ephedrines in man. I. The influence of urinary pH and urine volume output. J Pharmacol Exp Ther (1968) 1.05
The absorption and excretion of pentazocine after administration by different routes. Br J Anaesth (1971) 1.05
Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors. Xenobiotica (2004) 1.05
Evidence that aspartic acid 301 is a critical substrate-contact residue in the active site of cytochrome P450 2D6. J Biol Chem (1995) 1.05
Pharmacokinetics of local anaesthetics. Br J Anaesth (1986) 1.04
Pethidine revisited: plasma concentrations and effects after intramuscular injection. Br J Anaesth (1975) 1.04
Metabolic oxidation on aliphatic basic nitrogen atoms and their -carbon atoms--some unifying principles. J Pharm Pharmacol (1971) 1.04
Journal impact factors: a 'bioequivalence' issue? Br J Clin Pharmacol (2001) 1.04
Modified-release hydrocortisone for circadian therapy: a proof-of-principle study in dexamethasone-suppressed normal volunteers. Clin Endocrinol (Oxf) (2007) 1.04
Effects of beta-adrenoceptor antagonists on the pharmacokinetics of lignocaine. Br J Clin Pharmacol (1984) 1.03
Poisoning-associated deaths for England and Wales between 1973 and 1980. Hum Toxicol (1984) 1.02
The systemic availability of a slow release rectal preparation of lignocaine [proceedings]. Br J Clin Pharmacol (1978) 1.02
Amiodarone pharmacokinetics. Br J Clin Pract Suppl (1986) 1.02
The antitussive effect of dextromethorphan in relation to CYP2D6 activity. Br J Clin Pharmacol (1999) 1.01
The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations. Clin Pharmacokinet (1986) 1.00
The pharmacokinetics of methadone in healthy subjects and opiate users. Br J Clin Pharmacol (1997) 1.00
Urinary excretion of methylamphetamine in man. Nature (1965) 1.00
Identification and quantitative determination of some metabolites of methadone, isomethadone and normethadone. J Pharm Pharmacol (1971) 0.99
Testing for bimodality in frequency distributions of data suggesting polymorphisms of drug metabolism--hypothesis testing. Br J Clin Pharmacol (1989) 0.99
Acebutolol in hypertension: relationships between drug concentration and effects. Eur J Clin Pharmacol (1978) 0.99
Testing for bimodality in frequency distributions of data suggesting polymorphisms of drug metabolism--histograms and probit plots. Br J Clin Pharmacol (1989) 0.99
The relation between blood levels and urinary excretion of amphetamine under controlled acidic and under fluctuating urinary pH values using [14C] amphetamine. J Pharm Pharmacol (1969) 0.98
Determination of metformin in biological samples. Br J Clin Pharmacol (1978) 0.98
The distribution, metabolism and excretion of mexiletine in man. Postgrad Med J (1977) 0.97
The influence of methyl substitution on the N-demethylation and N-oxidation of normethadone in animal species. J Pharm Pharmacol (1971) 0.97
The absorption of nicotine-1'-N-oxide and its reduction in the gastro-intestinal tract in man. Xenobiotica (1973) 0.97
A possible index of fatal drug toxicity in humans. Med Sci Law (1983) 0.97
In-vivo indices of enzyme activity: the effect of renal impairment on the assessment of CYP2D6 activity. Pharmacogenetics (1999) 0.96
Absorption of (-)-nicotine-l-N-oxide in man and its reduction in the gastrointestinal tract. J Pharm Pharmacol (1970) 0.96
Backtracking booze with Bayes--the retrospective interpretation of blood alcohol data. Br J Clin Pharmacol (1991) 0.95
Towards a quantitative framework for the prediction of DDIs arising from cytochrome P450 induction. Curr Drug Metab (2009) 0.95
The absorption, distribution and excretion of pentazocine in man after oral and intravenous administration. J Pharm Pharmacol (1970) 0.95
Disposition kinetics of ropivacaine in humans. Anesth Analg (1989) 0.95
The absorption and urinary excretion in man of fenfluramine and its main metabolite. J Pharm Pharmacol (1967) 0.94
An analysis of the inter-subject variation in the metabolism of pentazocine. J Pharm Pharmacol (1974) 0.94
The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol. Br J Clin Pharmacol (1984) 0.94
Inhibition of metoprolol metabolism by chloroquine and other antimalarial drugs. J Pharm Pharmacol (1990) 0.94
The use of tolbutamide-induced hypoglycemia to examine the intraislet role of insulin in mediating glucagon release in normal humans. J Clin Endocrinol Metab (1997) 0.93
The influence of alkyl substitution in acids on their performance in the buccal absorption test. J Pharm Pharmacol (1968) 0.93
Bupivacaine hydrochloride: laboratory and clinical studies. Anesthesiology (1970) 0.93
Analysis of barbiturates in blood by high-performance liquid chromatography. J Chromatogr (1981) 0.93
Forensic aspects of the metabolism and excretion of cannabinoids following oral ingestion of cannabis resin. J Pharm Pharmacol (1984) 0.92
A rapid quantitative assay of intact paracetamol tablets by reflectance near-infrared spectroscopy. Analyst (1999) 0.92
Prediction of metabolic drug clearance in humans: in vitro-in vivo extrapolation vs allometric scaling. Xenobiotica (2006) 0.92
Optimum use of paper, thin-layer and gas-liquid chromatography for the identification of basic drugs. 3. Gas-liquid chromatography. J Chromatogr (1974) 0.92
Relevance of induction of human drug-metabolizing enzymes: pharmacological and toxicological implications. Br J Clin Pharmacol (1996) 0.92